Michael R Megna Kiniksa Pharmaceuticals, Ltd. (KNSA) insider trading activity

Michael R Megna is CHIEF ACCOUNTING OFFICER of Kiniksa Pharmaceuticals, Ltd.. Currently has a direct ownership of 26,528 shares of KNSA, which is worth approximately $578,310. The most recent transaction as insider was on Sep 01, 2023, when has been sold 3,933 shares (Class A Common Share) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 26.5K

19.21% 3M change

56.0% 12M change

Total Value Held $578,310

Michael R Megna Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 01 2023	BUY Exercise of conversion of derivative security	-	3,933 Added 18.36%	17,491 Class A Common Share
Jul 15 2023	BUY Grant, award, or other acquisition	$7,175 $12.35 p/Share	581 Added 4.11%	13,558 Class A Common Share
Apr 10 2023	SELL Payment of exercise price or tax liability	$12,370 $10.71 p/Share	1,155 Reduced 8.17%	12,977 Class A Common Share
Apr 10 2023	BUY Exercise of conversion of derivative security	-	3,933 Added 21.77%	14,132 Class A Common Share
Mar 20 2023	SELL Payment of exercise price or tax liability	$7,061 $11.12 p/Share	635 Reduced 5.86%	10,199 Class A Common Share
Mar 20 2023	BUY Exercise of conversion of derivative security	-	2,163 Added 16.64%	10,834 Class A Common Share
Mar 16 2023	SELL Payment of exercise price or tax liability	$2,532 $11.46 p/Share	221 Reduced 2.49%	8,671 Class A Common Share
Mar 16 2023	BUY Exercise of conversion of derivative security	-	774 Added 8.01%	8,892 Class A Common Share
Jan 15 2023	BUY Grant, award, or other acquisition	$6,730 $9.56 p/Share	704 Added 7.98%	8,118 Class A Common Share
Oct 04 2022	SELL Payment of exercise price or tax liability	$740 $14.23 p/Share	52 Reduced 0.7%	7,414 Class A Common Share
Oct 04 2022	BUY Exercise of conversion of derivative security	-	175 Added 2.29%	7,466 Class A Common Share
Sep 02 2022	SELL Payment of exercise price or tax liability	$2,608 $11.44 p/Share	228 Reduced 3.03%	7,291 Class A Common Share
Sep 02 2022	BUY Exercise of conversion of derivative security	-	775 Added 9.34%	7,519 Class A Common Share
Jul 15 2022	BUY Grant, award, or other acquisition	$6,721 $9.56 p/Share	703 Added 9.44%	6,744 Class A Common Share
Mar 21 2022	SELL Payment of exercise price or tax liability	$12,298 $10.98 p/Share	1,120 Reduced 15.64%	6,041 Class A Common Share
Mar 21 2022	BUY Exercise of conversion of derivative security	-	3,231 Added 31.09%	7,161 Class A Common Share
Mar 16 2022	SELL Payment of exercise price or tax liability	$2,725 $10.13 p/Share	269 Reduced 6.41%	3,930 Class A Common Share
Mar 16 2022	BUY Exercise of conversion of derivative security	-	775 Added 15.58%	4,199 Class A Common Share
Jan 15 2022	BUY Grant, award, or other acquisition	$6,288 $9.63 p/Share	653 Added 16.02%	3,424 Class A Common Share
Jul 15 2021	BUY Grant, award, or other acquisition	$6,756 $11.49 p/Share	588 Added 17.51%	2,771 Class A Common Share
Dec 31 2020	BUY Grant, award, or other acquisition	$6,083 $15.02 p/Share	405 Added 15.65%	2,183 Class A Common Share
Jun 30 2020	BUY Grant, award, or other acquisition	$6,096 $9.51 p/Share	641 Added 26.5%	1,778 Class A Common Share

MRM

Michael R Megna

CHIEF ACCOUNTING OFFICER

Hamilton, D0

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KNSA shares.

Notify only if

Value

Insider Trading

Get notified when an Kiniksa Pharmaceuticals, Ltd. insider buys or sells KNSA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Kiniksa Pharmaceuticals, Ltd.

Track Activities on KNSA

Account